zedie posted: " Abstract BACKGROUND Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treat" Read on blog or Reader SOMEONE SOMEWHERE Read on blog or Reader Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma zedie March 2 Abstract BACKGROUND Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple myeloma is needed. METHODS In this phase 3 trial, we randomly assigned 709 transplantation-eligible patients with […] Read more of this post Comment Like You can also reply to this email to leave a comment.

SOMEONE SOMEWHERE © 2024. Manage your email settings or unsubscribe. Get the Jetpack app Subscribe, bookmark, and get real-time notifications - all from one app! Automattic, Inc. - 60 29th St. #343, San Francisco, CA 94110